Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Daiichi Sankyo to Invite Joint Drug Discovery Projects for Open Innovation
March 21, 2011
- Janssen: Stelara for Psoriasis
March 21, 2011
- Eisai Ties Up with Epizyme for Cancer Treatments
March 21, 2011
- Sales of Ethical Drugs Up 3.9% in January: Crecon Research & Consulting
March 21, 2011
- Dr Lechleiter of Eli Lilly Calls For Full Introduction of Premium for Development of New Drugs
March 21, 2011
- GSK: Arixtra for Treatment of Acute DVT, Acute PTE
March 21, 2011
- NIBIO Opens Toxicogenomics DB
March 21, 2011
- Yakult Licenses Perifosine from Aeterna Zentaris
March 21, 2011
- Kyowa Kirin Begins PIII for Pegfilgrastim
March 21, 2011
- Pfizer to Enhance Focus on Infectious Diseases
March 21, 2011
- Janssen Begins PIII Trial of Concerta for AD/HD in Adults
March 21, 2011
- Analysts Question Kyowa Kirin's Acquisition of ProStrakan
March 21, 2011
- MediciNova Obtains Patent on Ibudilast to Treat Drug Dependence
March 21, 2011
- Carna Biosciences to Accelerate Licensing of Its Own Compounds
March 21, 2011
- PIII Results for Halaven to Be Published in The Lancet
March 21, 2011
- Citigroup Sees Strong Outlook for Nippon Shinyaku's Vidaza
March 21, 2011
- Pfizer, Daiichi Sankyo Alert Med. Institutions about Use of Prevnar, ActHIB
March 21, 2011
- Januvia Ranked No. 1 in HP, GP Markets: RepTrack Survey
March 21, 2011
- JMA Urges Korosho to Make Quick Decision Regarding ActHIB, Prevnar
March 21, 2011
- Massive Earthquake, Tsunami Hit Northern Japan Paralyzing Business Activities
March 21, 2011
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…